Effects of intra‐arterial prostaglandin E₁ in patients with peripheral arterial occlusive disease

Abstract

The effects of intraarterially administered prostaglandin E1 (PGE1) on macrocirculatory, microcirculatory and metabolic parameters in patients with peripheral arterial occlusive disease were studied. Nutritive calf muscle blood flow, as determined with the xenon-clearance technique, and muscle tissue oxygen pressure increased markedly in patients with obliterations of the femoral artery. Transcutaneous PO2 as indicator for cutaneous blood flow increased in prestenotic regions dose-dependently whereas there was a clear poststenotic decrease during the infusion period. High lactate/pyruvate ratios in the femoral vein were significantly decreased by PGE1 treatment. PO2 in the femoral vein increased significantly. Thus, PGE1 has some beneficial effects on muscle circulation in these patients.

Treatment with oxygen-ozone therapy in hemodialysis patients

“…Medications show little verified benefit. 15,16 Diffuse distal lesions and vascular calcification in dialysed patients often impair the angioplasty success; moreover serious comorbid conditions make hemodialysed patients poor candidates for surgical procedures and contribute to increase mortality rate for those who undergo limb-sparing procedures. 8 Hence non-invasive therapeutic procedures are desirable for this class of patients.…”

Prostaglandin E1in critical limb ischemia transcutaneous PO2: A predictor of efficacy?

“…Since prostaglandin E~ was first used by Carlson in 1973 [3,4], its effectiveness has been proved in many clinical studies [1,[6][7][8]12,13,16,17]. The mode of action relies on vasodilation, improvement of erythrocyte flexibility, inhibition of ischemia-induced neutrophil activation, reduction of platelet aggregation, and increased fibrinolytic activity [2,14,15].…”

Intraindividual evaluation of the optimal PGE1application route in critical limb ischemia

“…The results of several studies indicate the clinical effectiveness of intraarterial infusion of PGEt as a treatment for critical limb ischemia [1,2,4,6]. Under routine conditions, i.a.…”

“…As first described by Carlson in 1973 [1], prostaglandin Et (PGE1) is widely used in the treatment of arterial occlusive disease of different stages [1][2][3][4][5][6][7]. Clinical improvement has been observed during intraarterial as well as during intravenous administration of PGE1.…”